Found 137 clinical trials
-
Phase 2 trial
-
Accepting pediatric ages
-
Currently Recruiting
CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)
CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)
- 332 views
- 08 Nov, 2020
- 1 location
-
Phase 4 trial
-
Accepting pediatric ages
-
Accepting adults
-
Currently Recruiting
Do You Have Osteoporosis?
Do You Have Osteoporosis?
- 1122 views
- 08 Nov, 2020
- 1 location
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For females only
-
Family Medicine
-
Currently Recruiting
Management of Low-risk DCIS
A substantial number of DCIS lesions will never form a health hazard, particularly if it concerns slow-growing low-grade DCIS. This implies that many women might be unnecessarily going through
- 410 views
- 08 Nov, 2020
- 1 location
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Family Medicine
-
Currently Recruiting
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ
carcinoma in situ (DCIS) patients, the aforementioned two studies included a proportional patients who had young age and negative estrogen receptor (ER) status tumor. Previous studies and our studies
- 9 views
- 12 Aug, 2019
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For females only
-
Family Medicine
-
Currently Recruiting
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
The primary objective of this study is to compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in
- 46 views
- 07 Nov, 2020
- 2 locations
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Gastroenterology
-
Currently Recruiting
Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast
Following breast-conserving surgery (BCS) for localized ductal carcinoma in situ (DCIS) of the breast, whole-breast irradiation (WBRT) is a standard of care, reducing the absolute rate of in
- 15 views
- 02 Aug, 2020
- 13 locations
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For females only
-
Family Medicine
-
Currently Recruiting
Neoadjuvant Multi-epitope HER2 Peptide Vaccine in Patients With HER2-expressing DCIS
carcinoma in situ (DCIS). The ultimate goal of this vaccine is to prevent future invasive breast cancer among patients who are diagnosed with DCIS. However, the focus of this study is safety and efficacy
- 20 views
- 10 Jun, 2019
- 2 locations
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For females only
-
Family Medicine
-
Currently Recruiting
Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery
the side effects of doxorubicin hydrochloride liposome and to see how well it works in treating women with ductal carcinoma in situ undergoing surgery.
- 0 views
- 07 Nov, 2020
- 1 location
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Family Medicine
-
Currently Recruiting
Intra-operative Radiotherapy For Women With Ductal Carcinoma in Situ Breast Cancer
Whether the patients with low grade ductal carcinoma in situ breast cancer should accept radiationtherapy is uncertain.Radiation therapy uses high-energy x-rays to damage tumor cells. Giving
- 0 views
- 08 Nov, 2020
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For females only
-
Family Medicine
-
Currently Recruiting
Comparing an Operation to Monitoring With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS
is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AM approach does not yield inferior cancer or quality of life outcomes compared to surgery.
- 1205 views
- 28 Nov, 2020
- 133 locations